Back to Journals » Open Access Journal of Clinical Trials » Volume 2

Retrospective analysis of a South African cardiovascular trial site’s patient retention rates

Authors Burgess LJ , Sulzer NU

Published 26 November 2010 Volume 2010:2 Pages 163—166


Review by Single anonymous peer review

Peer reviewer comments 2

Lesley J Burgess, Nicole U Sulzer
TREAD Research/Cardiology Unit, Department of Internal Medicine, Tygerberg Hospital and University of Stellenbosch, Parow, South Africa

Introduction: Patient dropouts negatively affect study cost and validity of study results.
Objectives: To investigate the attrition rate and reasons for patient discontinuations at a cardiovascular trial site in South Africa.
Methods: Studies conducted over the past 10 years were randomly selected and retrospectively examined for attrition rates and reasons for patient discontinuation.
Results: A total of 50 studies with a duration ranging from 3 to 45 months were examined. A total of 1386 patients were randomized. Of these, 88.9% completed all scheduled study visits, resulting in a mean 11.1% (n = 154) attrition rate. Reasons for discontinuation included death (39.6%), withdrawal of consent (33.1%), adverse events (22.7%), and relocation (4.5%). There were no patients lost to follow-up.
Conclusion: The low attrition rate and absence of any patients lost to follow-up are the result of a dedicated retention plan in which each site staff member has a crucial role to play in keeping patients motivated and interested in participating in a clinical trial.

Keywords: clinical trials, lost to follow-up, attrition

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.